Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Slides:

Advertisements

Similar presentations

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Advertisements

Gestational hypothyroidism: development of mild hypothyroidism in early pregnancy in previously euthyroid women Karen R. Hammond, D.N.P., C.R.N.P., Nicholas.

Male contraception Fertility and Sterility

Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response William L. Ledger, Bart C.J.M. Fauser, Paul.

Evaluation of basal estradiol levels in assisted reproductive technology cycles2 John L Frattarelli, M.D., Paul A Bergh, M.D., Michael R Drews, M.D.,

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF Bart C.J.M. Fauser, Michael.

The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome

Michael P Steinkampf, M. D. , Sejal P Dharia, M. D

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization–embryo.

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Zeev Shoham, M.D. Fertility and Sterility

High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage Luciano G Nardo,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity Helen Sullivan,

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro.

A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency Ziad R. Hubayter, M.D., M.P.H., Vaishali.

Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome Annie A. Guedikian, B.S.,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Does Testosterone Have a Role in Erectile Function?

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part II. dose-proportionality and gonadotropin suppression after.

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

F. Estelle R. Simons, MD, FRCPCa, Xiaochen Gu, PhDb, Keith J

Kurt T Barnhart, M. D. , M. S. C. E. , Thomas Bader, M. D

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Hongxia Li, M. D. , Steven T Nakajima, M. D. , Jiangang Chen, M. D

Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation Allison Styne-Gross, M.D., Karen.

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Circulating Bioactive and Immunoreactive Recombinant Human Follicle-Stimulating Hormone (Org 32489) After Administration to Gonadotropin-Deficient Subjects

Antecubital vein venous sampling does not distort circulating levels of peptide and sex steroid hormones Michael P. Diamond, M.D., Michael Kruger, M.S.,

Matthew S. Christman, M. D. , Suzanne R. Gudeman, M. D. , Justin J

Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population Joris M van Montfrans, M.D., Annemieke Hoek,

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal.

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil.,

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part I. absolute bioavailability of 0.25 mg of ganirelix after.

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Use of recombinant human chorionic gonadotropin in ovulation induction

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Presentation transcript:

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D., Karen R Hammond, M.S.N., C.R.N.P., John E Nichols, M.D., Scott H Slayden, M.D. Fertility and Sterility Volume 80, Issue 1, Pages 99-102 (July 2003) DOI: 10.1016/S0015-0282(03)00566-1

FIGURE 1 Serum FSH concentrations after administration of rFSH 300 IU IM or SC. Steinkampf. Obesity and rFSH absorption: SC vs. IM. Fertil Steril 2003. Fertility and Sterility 2003 80, 99-102DOI: (10.1016/S0015-0282(03)00566-1)

FIGURE 2 Correlation between BMI and extent of absorption (area under curve, or AUC) after 300 IU of rFSH was injected IM or SC Strength of linear relationships tested with Pearson product moment correlation. RIM = −0.637, P=.0059; RSC = −0.526, P=.030. Steinkampf. Obesity and rFSH absorption: SC vs. IM. Fertil Steril 2003. Fertility and Sterility 2003 80, 99-102DOI: (10.1016/S0015-0282(03)00566-1)